Last reviewed · How we verify

Qfitlia — Competitive Intelligence Brief

Qfitlia (FITUSIRAN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antithrombin-directed RNA Interaction [EPC]. Area: Rare Disease.

marketed Antithrombin-directed RNA Interaction [EPC] Rare Disease Oligonucleotide Live · refreshed every 30 min

Target snapshot

Qfitlia (FITUSIRAN) — Genzyme Corp. Qfitlia works by using small RNA molecules to block the production of antithrombin, a protein that can interfere with blood clotting.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Qfitlia TARGET FITUSIRAN Genzyme Corp marketed Antithrombin-directed RNA Interaction [EPC] 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antithrombin-directed RNA Interaction [EPC] class)

  1. Genzyme Corp · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Qfitlia — Competitive Intelligence Brief. https://druglandscape.com/ci/fitusiran. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: